{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:17:34Z","timestamp":1770477454040,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2002,1]]},"DOI":"10.1124\/jpet.300.1.64","type":"journal-article","created":{"date-parts":[[2003,1,10]],"date-time":"2003-01-10T18:30:34Z","timestamp":1042223434000},"page":"64-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Electrophysiologic Characterization of the Antipsychotic Drug Sertindole in a Rabbit Heart Model of Torsade de Pointes: Low Torsadogenic Potential Despite QT Prolongation"],"prefix":"10.1016","volume":"300","author":[{"given":"Lars","family":"Eckardt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter","family":"Breithardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm","family":"Haverkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.300.1.64_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(00)80728-X","article-title":"MiRP1 forms I(Kr) potassium channels with HERG and is associated with cardiac arrhythmia.","volume":"97","author":"Abbott","year":"1999","journal-title":"Cell"},{"key":"10.1124\/jpet.300.1.64_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004850-199803003-00002","article-title":"Pharmacological differentiation of classical and novel antipsychotics.","volume":"13","author":"Arnt","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1124\/jpet.300.1.64_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of evidence.","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.300.1.64_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00005344-199008000-00014","article-title":"QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions.","volume":"16","author":"Carlsson","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/jpet.300.1.64_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00005344-199908000-00009","article-title":"Electropharmacologic characteristics of ventricular proarrhythmia induced by ibutilide.","volume":"34","author":"Chen","year":"1999","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/jpet.300.1.64_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1461-5347(99)00172-8","article-title":"QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development.","volume":"2","author":"Crumb","year":"1999","journal-title":"Pharm Sci Technol Today"},{"key":"10.1124\/jpet.300.1.64_bib7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00004714-199812000-00011","article-title":"Prolongation of QT interval in isolated feline hearts by antipsychotic drugs.","volume":"18","author":"Drici","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/jpet.300.1.64_bib8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0008-6363(98)00043-1","article-title":"Experimental models of torsade de pointes.","volume":"39","author":"Eckardt","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1124\/jpet.300.1.64_bib9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00005344-199809000-00013","article-title":"Drug-related torsade de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol and erythromycin.","volume":"32","author":"Eckardt","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/jpet.300.1.64_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/00005344-200012000-00005","article-title":"Modification of stretch-induced shortening of repolarization by streptomycin in the isolated rabbit heart.","volume":"36","author":"Eckardt","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/jpet.300.1.64_bib11","first-page":"12","article-title":"Pharmacokinetics and drug interactions: update for new antipsychotics.","volume":"11","author":"Ereshefsky","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/jpet.300.1.64_bib12","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1540-8159.1995.tb06988.x","article-title":"Computer analysis of monophasic action potentials: manual validation and clinically pertinent applications.","volume":"18","author":"Franz","year":"1995","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1124\/jpet.300.1.64_bib13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/13651509809115372","article-title":"The QT interval and the atypical antipsychotic sertindole.","volume":"2","author":"Fritze","year":"1998","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1124\/jpet.300.1.64_bib14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0008-6363(00)00119-X","article-title":"The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.","volume":"47","author":"Haverkamp","year":"2000","journal-title":"Cardiovasc Res"},{"key":"10.1124\/jpet.300.1.64_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0735-1097(97)00190-3","article-title":"Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest.","volume":"30","author":"Haverkamp","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/jpet.300.1.64_bib16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-121-7-199410010-00009","article-title":"Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.","volume":"121","author":"Hohnloser","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1124\/jpet.300.1.64_bib17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1540-8167.1995.tb00368.x","article-title":"Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.","volume":"6","author":"Hohnloser","year":"1995","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1124\/jpet.300.1.64_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0033-3182(95)71609-7","article-title":"The association between intravenous haloperidol and torsades de pointes. Three cases and a literature review.","volume":"36","author":"Hunt","year":"1995","journal-title":"Psychosomatics"},{"key":"10.1124\/jpet.300.1.64_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0014-2999(97)01242-9","article-title":"The antipsychotic drug sertindole is a specific inhibitor of alpha1A-adrenoceptors in rat mesenteric small arteries.","volume":"336","author":"Ipsen","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.300.1.64_bib20","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1001\/archinte.1997.00440380123013","article-title":"Torsade de pointes and low-dose oral haloperidol.","volume":"157","author":"Jackson","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1124\/jpet.300.1.64_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-3223(87)90135-1","article-title":"Iatrogenic torsade de pointes induced by thioridazine.","volume":"22","author":"Kiriike","year":"1987","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.300.1.64_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00000441-199506000-00003","article-title":"Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication.","volume":"309","author":"Krahenbuhl","year":"1995","journal-title":"Am J Med Sci"},{"key":"10.1124\/jpet.300.1.64_bib23","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1161\/01.CIR.94.10.2535","article-title":"Sex difference in risk of torsade de pointes with d,l-sotalol.","volume":"94","author":"Lehmann","year":"1996","journal-title":"Circulation"},{"key":"10.1124\/jpet.300.1.64_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1124\/jpet.300.1.64_bib25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/(SICI)1099-1077(199808)13:6<413::AID-HUP12>3.0.CO;2-A","article-title":"The safety of risperidone: a post-marketing study in 7684 patients.","volume":"13","author":"Mackay","year":"1998","journal-title":"Hum Psychopharmacol"},{"key":"10.1124\/jpet.300.1.64_bib26","first-page":"79","article-title":"The effects of sertindole and its metabolites on cardiac ion channels and action potentials (Abstract).","volume":"525","author":"Maginn","year":"2000","journal-title":"J Physiol Lond"},{"key":"10.1124\/jpet.300.1.64_bib27","doi-asserted-by":"crossref","first-page":"12329","DOI":"10.1073\/pnas.210244497","article-title":"A structural basis for drug-induced long QT syndrome.","volume":"97","author":"Mitcheson","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.300.1.64_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200015040-00003","article-title":"Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.","volume":"15","author":"Pezawas","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1124\/jpet.300.1.64_bib29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0022-3565(24)37654-2","article-title":"The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.","volume":"286","author":"Rampe","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.300.1.64_bib30","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1540-8159.1998.tb00148.x","article-title":"Taking the \u201cidio\u201d out of \u201cidiosyncratic\u201d: predicting torsades de pointes.","volume":"21","author":"Roden","year":"1998","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1124\/jpet.300.1.64_bib31","doi-asserted-by":"crossref","first-page":"73A","DOI":"10.1016\/S0735-1097(86)80032-8","article-title":"Clinical features and basic mechanisms of quinidine-induced arrhythmias.","volume":"8","author":"Roden","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/jpet.300.1.64_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.CIR.30.1.17","article-title":"Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias.","volume":"3","author":"Selzer","year":"1964","journal-title":"Circulation"},{"key":"10.1124\/jpet.300.1.64_bib33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/BF02245618","article-title":"A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia.","volume":"124","author":"van Kammen","year":"1996","journal-title":"Psychopharmacol Ser (Berl)"},{"key":"10.1124\/jpet.300.1.64_bib34","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/01.CIR.91.3.864","article-title":"Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block.","volume":"91","author":"Vos","year":"1995","journal-title":"Circulation"},{"key":"10.1124\/jpet.300.1.64_bib35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/026988110101500212","article-title":"Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.","volume":"15","author":"Wilton","year":"2001","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.300.1.64_bib36","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1023\/A:1015935031933","article-title":"Phosphatidylserine as a determinant for the tissue distribution of weakly basic drugs in rats.","volume":"10","author":"Yata","year":"1990","journal-title":"Pharmacol Res"},{"key":"10.1124\/jpet.300.1.64_bib37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.RES.84.9.989","article-title":"Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.","volume":"84","author":"Zhang","year":"1999","journal-title":"Circ Res"},{"key":"10.1124\/jpet.300.1.64_bib38","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1176\/ajp.154.6.782","article-title":"Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.","volume":"154","author":"Zimbroff","year":"1997","journal-title":"Am J Psychiatry"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524354187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524354187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.300.1.64","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T23:11:41Z","timestamp":1740006701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524354187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["S0022356524354187"],"URL":"https:\/\/doi.org\/10.1124\/jpet.300.1.64","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2002,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Electrophysiologic Characterization of the Antipsychotic Drug Sertindole in a Rabbit Heart Model of Torsade de Pointes: Low Torsadogenic Potential Despite QT Prolongation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.300.1.64","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2002 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}